News | May 30, 2024
Merck inks MoU with KAIST to advance scientific collaboration
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The collaboration aims to bolster healthcare entrepreneurship
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Lupin updates on shipment of Mirabegron ER Tablets
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
